USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
KINETA, INC.
Address:
219 Terry Ave N. Suite 300
SEATTLE, WA
Phone:
N/A
URL:
N/A
EIN:
126156679
DUNS:
809832558
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,184,750.00 2
SBIR Phase II $2,836,489.00 1

Award List:

Agonists of the RIG-I Innate Immune Pathway

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$585,307.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is a tremendous commercial demand for new antiviral products with novel mechanisms of action and which target a broad spectrum of viruses. Most previous and ongoing pharmaceutical development programs involve scre ening for inhibitors of essential virus… More

Development of Kv1.3 channel blocker ShK-186 as a therapy for multiple sclerosis

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$599,443.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Multiple sclerosis (MS) affects approximately 400,000 Americans and constitutes a progressive, disabling disease for which current therapies are inadequate. This application describes the nonclinical development of ShK- 186, a novel Kv1.3 potassium channel… More

Agonists of the RIG-I Innate Immune Pathway

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$2,836,489.00
Agency:
HHS
Principal Investigator:
Shawn P. Iadonato – 206-378-0400
Abstract:
DESCRIPTION (provided by applicant): Through Phase I studies, we have identified five lead small molecule compounds with drug-like properties that activate innate immune response pathways and inhibit the replication of RNA viruses such as hepatitis C virus (HCV), influenza virus (FLU), and West… More